Agilent Technologies Inc. (A)
Agilent lowers annual revenue forecast on soft demand for medical equipment
Medical equipment maker Agilent lowered its annual revenue forecast on Wednesday, as it expects soft demand for its medical tools and equipment from smaller biotech companies.
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
What Analyst Projections for Key Metrics Reveal About Agilent (A) Q1 Earnings
Besides Wall Street's top -and-bottom-line estimates for Agilent (A), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended January 2025.
Agilent Technologies, Inc. (A) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Agilent Technologies, Inc. (NYSE:A ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:45 PM ET Company Participants Padraig McDonnell - President and CEO Robert McMahon - Senior VP and CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Good morning, everyone.
Agilent (A) Up 1.3% Since Last Earnings Report: Can It Continue?
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Is the Options Market Predicting a Spike in Agilent (A) Stock?
Investors need to pay close attention to Agilent (A) stock based on the movements in the options market lately.
Agilent CEO Padraig McDonnell sees 'long runway' in advancing therapeutics
Padraig McDonnell, Agilent CEO, joins 'Closing Bell Overtime' to talk investors day, its healthcare segment, and more.
Agilent Gains 5% in a Month: Should You Buy, Sell or Hold the Stock?
A's shares ride on the bright performance of the Agilent CrossLab Group segment and strategic acquisitions.
International Markets and Agilent (A): A Deep Dive for Investors
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Agilent Q4 Earnings Surpass Estimates, Revenues Increase Y/Y
A's fourth-quarter 2024 results benefit from strong demand in the ACG segment. However, declining sales in the Americas and China markets raise concerns.
Agilent Q4: Expecting Market Recovery In 2025
I reiterate a “Buy” rating on Agilent Technologies, Inc. with a one-year target price of $150 per share, driven by strategic growth and market recovery. Agilent's acquisition of BIOVECTRA will enhance its CDMO business, focusing on oligonucleotides and CRISPR therapeutics, and expand service offerings in peptide synthesis. Agilent's FY25 guidance includes 2.5%-3.5% core revenue growth and 5.8% adjusted EPS growth, aligned with market expectations and supported by segment-specific growth strategies.
Agilent Technologies, Inc. (A) Q4 2024 Earnings Call Transcript
Agilent Technologies, Inc. (NYSE:A ) Q4 2024 Results Conference Call November 25, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Vice President, Investor Relations Padraig McDonnell - President and CEO Bob McMahon - Senior Vice President and CFO Simon May - President, Life Sciences and Diagnostic Markets Group Phil Binns - President, Life Sciences & Applied Markets Group Angelica Riemann - President, Agilent CrossLab Group Mike Zhang - President, Applied Markets Group Conference Call Participants Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Vijay Kumar - Evercore ISI Jack Meehan - Nephron Research Dan Leonard - UBS Puneet Souda - Leerink Partners Tycho Peterson - Jefferies Brandon Couillard - Wells Fargo Doug Schenkel - Wolfe Research Michael Ryskin - Bank of America Dan Brennan - TD Cowen Operator Good afternoon. My name is Rob, and I will be your conference operator today.
